Chemours Company (CC) Q3 2026 Earnings
Adjusted EPS excludes items included in GAAP diluted EPS of $1.29. These include $150 million received under the PFAS insurance proceeds MOU (recorded as a reduction to SG&A), net litigation-related income of $138 million, a $50 million gain on sales of assets (Kuan Yin land) and $18 million of environmental charges.
How Did CC Stock React to Q3 2026 Earnings?
Did CC Beat Earnings? Q3 2026 Results
No. Chemours Company reported Q3 2026 earnings of $0.21 a share on Nov 2, 2026, missing the $0.26 consensus estimate by 18.5%. Revenue was $1.5B against a $1.5B estimate.
The Chemours Company delivered a mixed third quarter for fiscal 2026, posting adjusted EPS of $0.21 against a consensus estimate of $0.26, an 18.51% miss, even as revenue of $1.54 billion edged past expectations by 0.50% and grew 3.00% year over year. The gap between headline and underlying results was substantial: GAAP EPS of $1.29 was lifted by a $150 million PFAS insurance receipt booked as a reduction to SG&A, $138 million in net litigation-related income, and a $50 million gain on the Kuan Yin land sale, leaving adjusted profit well below what analysts had modeled. The clearest bright spot was Titanium Technologies, where a 10% TiO2 price increase drove segment revenue up 11% to $680 million and expanded Adjusted EBITDA margin nine points. Thermal and Specialized Solutions remained a drag, as Opteon refrigerant sales fell 22% lapping last year's AIM Act-driven channel fill, a dynamic that has drawn securities litigation scrutiny. Management guided Q4 Adjusted EBITDA of $160 million to $185 million and full-year Adjusted EBITDA of $775 million to $800 million.
- TT pricing up approximately 10% year over year on recent TiO2 price announcements, with pricing up across all regions
- TT volume growth of 1% from strength in North America, Latin America and APAC excluding China
- APM Performance Solutions net sales up 26% on order book strength in data center and semiconductor end markets
- Lower North American stationary AC aftermarket sales of TSS Opteon blends versus prior-year channel fill
- Higher costs across each business partially offset gains
- Receipt of $150 million in PFAS insurance proceeds under the New Jersey JCO-related MOU, recorded as a reduction to SG&A
- $50 million gain on sales of assets tied to the Kuan Yin land sale
“Our third-quarter results demonstrate strong year-over-year performance in TT and APM, reflecting pricing execution in TiO2 and increased demand across Performance Solutions' high-value AI infrastructure including data center and semiconductor end markets.”
Chemours Company CEO, on the earnings call
What Is Chemours Company's Outlook?
Q4 2026 guidance: - Consolidated net sales expected to decline 5% to 10% sequentially, driven by seasonality in TSS and TT. - Adjusted EBITDA of $160 million to $185 million; corporate expenses of about $40 million to $45 million. - Capex of $75 million to $85 million, with positive free cash flow. - TSS: sales down high-teens to low-twenties percent sequentially; Adjusted EBITDA of $105 million to $115 million. - TT: sales down high single digits to low teens percent; Adjusted EBITDA of $60 million to $65 million. - APM: sales up low-to-mid teens percent on Performance Solutions order strength and customer contractual obligations; Adjusted EBITDA of $40 million to $45 million. Full-year 2026 guidance: - Net sales growth of about 2% over 2025. - Adjusted EBITDA of $775 million to $800 million. - Capex of $220 million to $230 million. - Free cash flow conversion above 15% (estimated free cash flow of $120 million to $160 million). This includes the $150 million PFAS insurance receipt, partially offset by New Jersey and North Carolina settlement payments and Kuan Yin taxes. - Net leverage ratio below 4.2x in 2026.
CC YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $1.5B | $1.5B | +3.0% |
| Gross Profit | $231.0M | $235.0M | −1.7% |
| Net Income | $196.0M | $60.0M | +226.7% |
CC Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.